Genetic polymorphisms contributing to hearing loss in children treated with platinum agents: a systematic review and meta-analysis protocol.

ABSTRACT:

Introduction

The improved survival rates of children with cancer have heightened concerns about treatment-related chronic health conditions, including platinum-induced hearing loss (PIHL). Cisplatin and carboplatin, widely used in paediatric cancer therapies, frequently cause irreversible sensorineural hearing loss. PIHL affects 1.7-90.1% of patients exposed to these drugs, yet known risk factors-including age, cisplatin dosage, cranial radiation and co-treatment with ototoxic drugs-fail to fully explain interindividual variability. Genetic factors likely play a role in susceptibility to PIHL. Since genetic susceptibility in children may differ from adults, and given the critical window of auditory development, a focused investigation of paediatric genetic factors using quantitativ

SUBMITTER: Chavaz L 

PROVIDER: S-EPMC12443194 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature